Precigen (PGEN) Projected to Post Quarterly Earnings on Tuesday

Precigen (NASDAQ:PGEN) is projected to release its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Precigen to post earnings of ($0.02) per share and revenue of $27.9830 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. The company had revenue of $23.25 million during the quarter, compared to the consensus estimate of $20.81 million. Precigen had a negative net margin of 646.99% and a positive return on equity of 717.50%. On average, analysts expect Precigen to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Precigen Stock Down 2.1%

NASDAQ:PGEN traded down $0.12 during trading hours on Tuesday, hitting $5.30. 1,558,037 shares of the company’s stock traded hands, compared to its average volume of 4,446,822. The firm has a market cap of $1.89 billion, a P/E ratio of -4.52 and a beta of 1.00. The stock’s fifty day moving average price is $4.85 and its two-hundred day moving average price is $4.37. Precigen has a twelve month low of $1.57 and a twelve month high of $6.04. The company has a debt-to-equity ratio of 4.62, a quick ratio of 4.12 and a current ratio of 4.82.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Citizens Jmp increased their price target on shares of Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 14th. Wall Street Zen downgraded shares of Precigen from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Citigroup reiterated an “outperform” rating on shares of Precigen in a research report on Thursday, May 14th. HC Wainwright upped their price objective on shares of Precigen from $11.00 to $14.00 and gave the stock a “buy” rating in a research note on Thursday, May 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a research note on Friday, July 17th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $12.50.

Insider Buying and Selling at Precigen

In other Precigen news, CEO Helen Sabzevari sold 346,836 shares of Precigen stock in a transaction on Monday, June 29th. The shares were sold at an average price of $5.89, for a total transaction of $2,042,864.04. Following the completion of the sale, the chief executive officer owned 3,768,872 shares of the company’s stock, valued at approximately $22,198,656.08. The trade was a 8.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Donald P. Lehr sold 29,131 shares of the stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $4.36, for a total value of $127,011.16. Following the completion of the transaction, the insider directly owned 755,461 shares in the company, valued at approximately $3,293,809.96. This trade represents a 3.71% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 822,728 shares of company stock valued at $4,422,853 in the last three months. Insiders own 41.40% of the company’s stock.

Institutional Trading of Precigen

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Mason Investment Advisory Services Inc. bought a new stake in shares of Precigen in the 4th quarter valued at about $42,000. Abel Hall LLC acquired a new position in Precigen during the fourth quarter valued at approximately $44,000. NewEdge Advisors LLC bought a new stake in Precigen in the fourth quarter valued at approximately $45,000. Caitong International Asset Management Co. Ltd bought a new stake in Precigen in the third quarter valued at approximately $39,000. Finally, Cibc World Markets Corp acquired a new stake in Precigen in the fourth quarter worth $50,000. 33.51% of the stock is owned by institutional investors.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.